At the end of my medical training half a century ago, I asked my supervisor Georges Brouet, the eminent lung specialist who would go on to become Dean of the Paris Medical School, to allow me to write my dissertation on “Blood levels of active isoniazid and their practical relevance in the treatment of tuberculosis'. I defended this dissertation in 1961 and it caught the attention of Professor Etienne Bernard who awarded it a National Academy of Medicine prize.


The main practical findings were: the idea of fast and slow acetylators and of adjusting isoniazid dosage according to this metabolic status; relationships between neurotoxicological accidents caused by isoniazid and slow acetylator status; the consequences of impaired kidney and liver function on blood concentrations; and the need for dosage adjustment. It is interesting to see that, forty-five years later at a National Academy of Medicine meeting devoted to pharmacogenetics and pharmacogenomics presided over by the late, regretted Michel Bourel together with Raymond Ardaillou 1), a presentation by Michel Lhermitte et al. on genetic polymorphism and drugs addressed isoforms of N-acetyltransferase and the genotypic identification of fast and slow acetylators.
 

Advances in pharmacology and genetics have since shed light on an empirical observation that was originally based on simple clinical criteria and the results of bacteriologic tests on a reference strain conducted by Eugénie Bergogne-Berezin.

Summary

Introduction
Pierre Godeau 

Inter-ethnic, intra-ethnic and intra-individual variability in responsiveness to drugs
Jean-Paul Tillement

Genome and pharmacogenetics
Philippe Beaune

The (high)ways of pharmacogenetics and personalised medicine
Philippe Froguel 

Genomics in cancer and treatment
Fabien Calvo

Genetic determining factors for diabetic nephropathy: what is known today?
Michel Marre

Pharmacogenetics and coronary heart disease
Laurent Becquemont

The genetics of Alzheimer's disease
Philippe Amouyel

Pharmacogenetics of enzymes that metabolise drugs
Laurent Becquemont

Genetic variation of enzymes and drug targets: example of vitamin Kantagonists
Céline Vérstuyft

Pharmacogenetics and drug development: from research to labelling
François Alhenc-Gelas

Personalised treatment: a dream or tomorrow's reality?
Jacques Mallet 

Genetic testing and mass screening in the context of pharmacogenetics
Ségolène Aymé

Gene therapy, genetic engineering and ethics
Janine Chanteur

Organizers
Pr Patrice Jaillon, Pr Jean-François Giudicelli, Mme Béatrice Guardiola-Lemaitre
Authors
Ségolène Aymé, François Albenc-Gelas, Philippe Amouyel, Philippe Beaune, Laurent Becquemont, Fabien Calvo, Janine Chanteur, Pierre Godeau, Jacques Mallet, Michel Marre, Jean-Paul Tillement, Céline Verstuyft
Organizers
Pr Patrice Jaillon, Pr Jean-François Giudicelli, Mme Béatrice Guardiola-Lemaitre
Authors
Ségolène Aymé, François Albenc-Gelas, Philippe Amouyel, Philippe Beaune, Laurent Becquemont, Fabien Calvo, Janine Chanteur, Pierre Godeau, Jacques Mallet, Michel Marre, Jean-Paul Tillement, Céline Verstuyft
Category
Genomics
Publication type
Proceedings
Year
2010
Download the publication